Amyloid Plaque Reduction as a Surrogate Marker of Efficacy: Assessment of Amyloid PET and Change in CDR‐SB Utilizing Semi‐Mechanistic Model
Brian A Willis, Pratik Bhagunde, Robert Bell, Natasha Penner, Arnaud Charil, Michael C Irizarry, Steven Hersch, Larisa Reyderman · 2025
Read Amyloid Plaque Reduction as a Surrogate Marker of Efficacy: Assessment of Amyloid PET and Change in CDR‐SB Utilizing Semi‐Mechanistic Model by Brian A Willis, Pratik Bhagunde, Robert Bell, Natasha Penner, Arnaud Charil, Michael C Irizarry, Steven Hersch, Larisa Reyderman (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712377.txt.
Description
Brian Willis and co-authors model amyloid plaque loss as a stand-in for drug benefit in Alzheimer disease in this 2025 paper. Lecanemab is an antibody that binds amyloid protofibrils and clears plaques. Brain scans can track that clearing, but whether scan change predicts slower decline needed a test.
The team pooled data from two lecanemab trials, one phase two and one phase three. A semi-mechanistic model linked amyloid PET change to change on a dementia rating scale. Placebo data set the natural pace of decline in the model. Treated data then showed how plaque loss bends that pace. Simulations projected treatment effects over four years of use.
Catalog record
| CREATOR | Brian A Willis, Pratik Bhagunde, Robert Bell, Natasha Penner, Arnaud Charil, Michael C Irizarry, Steven Hersch, Larisa Reyderman |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |